Dynavax Technologies Corp.

NASDAQ:DVAX  
18.13
-0.72 (-3.82%)
Products, Regulatory

Clover Biopharmaceuticals And Dynavax Announce First Participants Dosed In COVID-19 Vaccine Study

Published: 03/24/2021 06:25 GMT
Dynavax Technologies Corp. (DVAX) - Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in Spectra, a Global Phase 2/3 Clinical Trial for Adjuvanted S-trimer Covid-19 Vaccine Candidate.
Interim Analysis of the Primary Endpoint Expected in the Middle of 2021.
Study is Expected to Enroll Over 22,000 Adult and Elderly Participants at Multiple Sites.